Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02629692 · ClinicalTrials.gov registry record · Phase 1
Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies
A Phase 1 study of Healthy (For Part A) and Chronic Myeloid Leukemia (for Part B and C), sponsored by Sun Pharma Advanced Research Company Limited.
- Active
- Registry status
- Phase 1
- Development phase
- 122
- Enrollment target
- 20
- Study locations
NCT02629692: Active Phase 1 study of Healthy (For Part A) and Chronic Myeloid Leukemia (for Part B and C), sponsored by Sun Pharma Advanced Research Company Limited.
NCT02629692 is a Phase 1 study of Healthy (For Part A) and Chronic Myeloid Leukemia (for Part B and C) that is active but no longer recruiting, run by Sun Pharma Advanced Research Company Limited. The registered enrollment target is 122 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (103% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02629692, a Phase 1 study of Healthy (For Part A) and Chronic Myeloid Leukemia (for Part B and C), is active but no longer recruiting, sponsored by Sun Pharma Advanced Research Company Limited.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 122 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase 1/2 study to determine safety, tolerability, pharmacokinetics, and anti-leukemic activity of Vodobatinib (K0706) in treatment-refractory/intolerant CML
Primary Outcome
Number of Participants with Adverse Events in Part A
Conditions Studied
Interventions
- DRUG Vodobatinib (K0706) capsules
Study Locations (20)
Maharashtra
- Prince Aly Khan Hospital - Mumbai
- Tata Memorial Hospital - Mumbai
- Sahyadri Specialty Hospital - Pune
California
- The Oncology Institute of Hope and Innovation, Innovative Clinical Research Institute - Downey
- UCLA Hematologic Malignancy Program - Los Angeles
Texas
- Baylor University Medical Center - Dallas
- MD Anderson Cancer Center - Houston
Other
- Cliniques Universitaires Saint-Luc - Brussels
- Debreceni Egyetem - Debrecen
Rhone
- Centre Léon Bérard - Lyon
- Centre Hospitalier Lyon Sud - Pierre-Bénite
Florida
- Mayo Clinic - Jacksonville
Georgia
- Board of Regents of the University System of Georgia - Augusta
New York
- Memorial Sloan Kettering Cancer Center - MAIN - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2016-06-27 |
| Est. Completion | 2026-08 |
| Phase | Phase 1 |
What the registry record for NCT02629692 still lists
NCT02629692 is an interventional study that assigns participants to a tested intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (103% higher).
The record links to 2 conditions, with Healthy (For Part A) appearing as the primary indexed condition, and to 1 intervention - of which Vodobatinib (K0706) capsules is the first listed.
NCT02629692 names 20 study sites across 14 states, led by Maharashtra, California, Texas.
Frequently Asked Questions
What is clinical trial NCT02629692 about?
NCT02629692 is a clinical study titled "Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies". Phase 1/2 study to determine safety, tolerability, pharmacokinetics, and anti-leukemic activity of Vodobatinib (K0706) in treatment-refractory/intolerant CML
What is the current status of trial NCT02629692?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 122 participants. The study started on 2016-06-27. Estimated completion is 2026-08.
What conditions does trial NCT02629692 study?
This clinical trial studies the following conditions: Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C).
What interventions are being tested in trial NCT02629692?
The interventions under investigation include: Vodobatinib (K0706) capsules (DRUG).
Who is sponsoring clinical trial NCT02629692?
This trial is sponsored by Sun Pharma Advanced Research Company Limited, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02629692 being conducted?
This trial has 20 study locations across California, Florida, Georgia, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02629692's enrollment target sits among peer trials
122 475th of 2000 higher than 1,525 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI